Novo Nordisk AS (XTER:NOV)
€ 99.51 -3.09 (-3.01%) Market Cap: 442.81 Bil Enterprise Value: 440.41 Bil PE Ratio: 35.07 PB Ratio: 27.45 GF Score: 91/100

Q2 2022 Novo Nordisk A/S Earnings Call (London-Based Investors) Transcript

Aug 05, 2022 / 12:15PM GMT
Release Date Price: €50.65 (-0.69%)
Lars Fruergaard Jorgensen;S;President
Novo Nordisk A;CEO & Member of Management Board

/- -

I'm Lars Fruergaard Jørgensen. I'm the CEO of Novo Nordisk. And with me, I have Camilla Sylvest from Commercial; Martin from Medical; and Karsten, our CFO. So we'll do a quick introduction and just the theme by making a few presentations here. We will be talking about the future, which is inherently risky. So stay alert on the risk factors and our forward-looking statement here.

On strategic aspirations, we have set these aiming at delivering strong contribution to society, the environment, but of course, also our shareholders. So we see that based on these aspirations, and we believe we're making good progress. We have exciting progress from an innovation point of view. Martin will talk a bit to that, as we really focused on raising the bar in diabetes and obesity and expand into some adjacent disease areas.

You can see our commercial execution is really strong, strong growth in the first half year here, a continuation of an accelerated growth trend

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot